Zeller Thomas, Rastan Aljoscha, Macharzina Roland, Beschorner Ulrich, Noory Elias
Universitäts-Herzzentrum Freiburg - Bad Krozingen, Südring 15, Bad Krozingen, 79189, Germany,
Curr Treat Options Cardiovasc Med. 2015 May;17(5):380. doi: 10.1007/s11936-015-0380-3.
Drug-coated balloons (DCBs) provide a novel method to locally deliver paclitaxel into the arterial wall without the need of a chronically implanted delivery system. Following the first positive pilot studies, two large pivotal trials have confirmed superiority of DCBs over plain old balloon angioplasty (POBA) in the treatment of TASC II A and B femoro-popliteal lesions. Even for more complex femoro-popliteal lesions such as long lesions and in-stent restenosis, single-center studies and small randomized studies have shown promising mid-term technical and clinical results. This review article summarizes the current knowledge about DCBs in femoro-popliteal interventions, supplements published guidelines with evidence-based recommendations, and discusses still unresolved needs.
药物涂层球囊（DCB）提供了一种无需长期植入给药系统即可将紫杉醇局部递送至动脉壁的新方法。在首批阳性的初步研究之后，两项大型关键试验证实了DCB在治疗TASC II A和B型股腘病变方面优于普通老式球囊血管成形术（POBA）。即使对于更复杂的股腘病变，如长病变和支架内再狭窄，单中心研究和小型随机研究也显示出了中期良好的技术和临床效果。这篇综述文章总结了目前关于DCB在股腘介入治疗方面的知识，用基于证据的建议补充已发表的指南，并讨论了尚未解决的需求。
